Interplay between the immune and skeletal cells in the regulation of inflammatory bone destruction

Japanese Journal of Clinical Immunology

Volumn 30, Issue 1, 2007, Pages 22-28

  Suematsu, Ayako ^a   Takayanagi, Hiroshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

CaMK; NFATcl; Osteoimmunology; RANKL; Th17

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR;

CARTILAGE; HUMAN; IMMUNOLOGY; OSTEOCLAST; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ARTHRITIS, RHEUMATOID; CARTILAGE; HUMANS; OSTEOCLASTS; RANK LIGAND; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 34247868978     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.30.22     Document Type: Article

References (29)

1. Theill, L. E., Boyle, W. J., and Penninger, J. M.: RANKL and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 20: 795–823, 2002.
2. Wong, B. R., et al.: TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272: 25190–25194, 1997.
3. Arron, J. R., and Choi, Y.: Bone versus immune system. Nature 408: 535–536, 2000.
4. Feldmann, M., and Maini, R. N.: Anti-TNF α therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol 19: 163–196, 2001.
5. Takayanagi, H. et al.: Tcell-mediatedregulation of osteoclastogenesis by signalling crosstalk between RANKL and IFN-γ. Nature 408: 600–605, 2000.
6. Takayanagi, H. et al.: RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature 416: 744–749, 2002.
7. Sato, K. et al.: Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203: 2673–2682, 2006.
8. Takayanagi, H. et al.: Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling for terminal differentiation of osteoclasts. Dev Cell 3: 889–901, 2002.
9. Koga, T. et al.: Costimulatorysignalsmediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428: 758–763, 2004.
10. Sato, K. et al.: Regulation of osteoclast diferentiation and function by the CaMK-CREB pathway. Nat Med 12: 1410–1416, 2006.
11. Takayanagi, H.: Inflammatory bone destruction and osteoimmunology. J Periodontal Res 40: 287–293, 2005.
12. Takayanagi, H. et al.: A new mechanism of bone destruction in rheumatoid arthritis: Synovial fibroblasts induce osteoclastogenesis. Biochem Biophys Res Commun 240: 279–286, 1997.
13. Pettit, A. R. et al.: TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159: 1689–1699, 2001.
14. Redlich, K. et al.: Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest 110: 1419–1427, 2002.
15. Takayanagi, H. et al.: Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J Clin Invest 104: 137–146, 1999.
16. Kong, Y. Y. et al.: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402: 304–309, 1999.
17. Miljkovic, D., and Trajkovic, V.: Inducible nitric oxide synthase activation by interleukin- 17. Cytokine Growth Factor Rev 15: 21–32, 2004.
18. Okada, Y., Nagase, H., and Harris, E.D., Jr.: Matrix metalloproteinases 1, 2, and 3 from rheumatoid synovial cells are sufficient to destroy joints. J Rheumatol 14 Spec No: 41–42, 1987.
19. Lagasse, E., and Weissman, I. L.: Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice. Cell 89: 1021–1031, 1997.
20. Takayanagi, H.: Mechanistic insight into osteoclast diferentiation in osteoimmunology. J Mol Med 83: 170–179, 2005.
21. Asagiri, M., and Takayanagi, H.: The molecular understanding of osteoclast diferentiation. Bone, 40: 251–264, 2007.
22. Naito, A. et al.: Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deicient mice. Genes Cells 4: 353–362, 1999.
23. Urushibara, M. et al.: The antirheumatic drug lelunomide inhibits osteoclastogenesis by interfering with receptor activator of NFkB ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum 50: 794–804, 2004.
24. Suematsu, A. et al.: Scientiic basis for the eicacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis. Mod Rheumatol. in press 2007.
25. hi osteoclast precursors but is essential for mature osteoclast formation in TNFα-mediated inflammatory arthritis. J Bone Miner Res 19: 207–213, 2004.
26. Kotake, S. et al.: IL-17 in synovial luids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 109: 1345–1352, 1999.
27. Takayanagi, H. et al.: Involvement of receptor activator of nuclear factor κB ligand/osteoclast diferentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43: 259–269, 2000.
28. Weitzmann, M. N., and Paciici, R.: Estrogen deiciency and bone loss: An inlammatory tale. J Clin Invest 116: 1186–1194, 2006.
29. Lee, S. K. et al.: T lymphocyte-deicient mice lose trabecular bone mass with ovariectomy. J Bone Miner Res 21: 1704–1712, 2006.